STOCK TITAN
  1. Home
  2. News
  3. LQDA

Liquidia Corp - LQDA STOCK NEWS

Welcome to our dedicated news page for Liquidia (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Liquidia's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Liquidia's position in the market.

News
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Liquidia (NASDAQ: LQDA) executives to provide business update at the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
conferences
-
News
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
Rhea-AI Summary
Liquidia (LQDA) announces legal victories clearing the path for YUTREPIA™ approval for PAH and PH-ILD treatment. United Therapeutics' legal actions and expired exclusivity for Tyvaso® impact the regulatory landscape.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
fda approval
-
News
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Liquidia Corporation (LQDA) reported financial results for 2023, preparing to launch YUTREPIA™ upon FDA approval. The Federal Circuit rejected United Therapeutics' request for rehearing on '793 Patent. The company aims to become a full-scale commercial entity in 2024. Financially, revenue increased to $17.5 million, but net loss rose to $78.5 million in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.36%
Tags
earnings
News
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
Rhea-AI Summary
Liquidia Corporation (LQDA) will report its full year 2023 financial results on March 13, 2024, with a webcast to discuss financial results and corporate updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
conferences earnings
-
News
Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress
Rhea-AI Summary
Liquidia Corporation (NASDAQ: LQDA) announced the presentation of data from the L606 clinical program at the Pulmonary Vascular Research Institute (PVRI) 2024 Annual Congress. L606 is an investigational, sustained-release formulation of treprostinil for treating patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The presentation will take place on February 2, 2024, in London, England. The poster will be available on the Company’s website after the presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
-
News
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
Rhea-AI Summary
Liquidia Corporation announces FDA update on YUTREPIA NDA for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The FDA is confirming the process for adding the PH-ILD indication as an amendment to the NDA for YUTREPIA, causing a delay in the action letter issuance. The FDA did not request additional clinical data and did not issue a new PDUFA goal date. The company remains committed to preparing for the final FDA approval of YUTREPIA. Litigation filed by United Therapeutics alleging patent infringement of U.S. Patent No. 10,716,793 and U.S. Patent No. 11,826,327 is ongoing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none
News
Liquidia Corporation Announces Updates to Operations Leadership
Rhea-AI Summary
Liquidia Corporation announced updates to its operations leadership, with CFO Michael Kaseta taking on the role of COO as well. The company also promoted Michael Hunter to Senior Vice President of Manufacturing Operations, while former COO Robert Lippe will transition out of the company. These changes come in anticipation of the potential approval and launch of YUTREPIA™ (treprostinil) inhalation powder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
none
-
News
Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
Rhea-AI Summary
Liquidia Corporation (LQDA) files counterclaims against United Therapeutics Corporation (UTHR) seeking dismissal of claims related to ‘793 patent and declaration that ‘327 patent is not infringed, invalid, and unenforceable in response to amended patent infringement complaint. Liquidia also asserts that UTHR failed to disclose prior art references and additional material information during prosecution of the ‘327 patent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
none
-
News
Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
Rhea-AI Summary
Liquidia Corporation (LQDA) enrolled the first PH-ILD patient in the open-label ASCENT study for YUTREPIA and confirmed with the FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications. The FDA has tentatively approved YUTREPIA for PH-ILD with a PDUFA goal date of January 24, 2024. Liquidia also reached an agreement with the FDA regarding the registration requirements for L606 using the 505(b)(2) regulatory pathway, requiring only a single Phase 3 placebo-controlled efficacy trial in PH-ILD patients to support indications for both PAH and PH-ILD. The company is preparing to initiate a global study for L606 in 2024 and continues to enroll patients in an ongoing open-label, multicenter safety study of L606 in U.S. patients with PAH or PH-ILD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.26%
Tags
none
News
Liquidia Corporation Announces $100 Million in New Financings
Rhea-AI Summary
Liquidia Corporation (LQDA) announced a $100 million capital raise through a private placement with Patient Square Capital and HealthCare Royalty, signaling confidence in the company's strategy and the value of its product YUTREPIA. The private placement of 7,182,532 shares of common stock at a purchase price of $10.442 per share is expected to yield gross proceeds of approximately $75.0 million. Additionally, an advance of $25.0 million was received from HealthCare Royalty under the current financing agreement. The company has now secured a total of $126 million in gross proceeds in the last month.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.02%
Tags
none
Stock LQDA logo
Liquidia Corp

Nasdaq:LQDA

LQDA Rankings

#2448 Ranked by Market Cap
#717 Ranked by Stock Gains
N/A Ranked by Dividends

LQDA Stock Data

1.06B
49.94M
12.42%
51.22%
9.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Durham

About LQDA

liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.